EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

Tumour necrosis factor-α inhibitors, immune-mediated inflammatory diseases, and bloodstream infections: results from a nationwide case-control study

Cæcilie Leding, Alessandra Meddis, Jon Gitz Holler, Johan Burisch, Tue Wenzel Kragstrup, Lone Skov, Thomas Benfield

Clinical Microbiology and Infection · 2026

DOI: 10.1016/j.cmi.2026.02.005 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Clinical Microbiology and Infection, 2026. Verfasst von Cæcilie Leding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark. Electronic address: Caecilie.leding@regio…. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Bacteremia, Sepsis, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Severe infection risk associated with tumour necrosis factor-α inhibitors (TNFis) remains a concern. We aimed to assess the association between TNFi and bloodstream infections (BSIs) in a population-based setting. METHODS: Nationwide, registry-based case-control study including all adults from 2010 to 2024 with a first-time microbiologically confirmed BSI (cases) compared with age and sex-matched controls from the general population. Users were defined as individuals with TNFi exposure within 6 months prior to the date of BSIs. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were estimated using conditional logistic regression. We further assessed risk variation by type of TNFi, pathogen, and underlying disease. RESULTS: We included 174,137 cases and 1 741 294 controls. Users had significantly increased odds of BSIs compared with nonusers (aOR, 1.41; 95% CI, 1.30-1.52), driven by increased odds among users of adalimumab and infliximab (aOR, 1.51; 95% CI, 1.33-1.72, and aOR, 2.01; 95% CI, 1.76-2.29). The use of certolizumab pegol and etanercept was associated with lower odds of BSIs, and golimumab with higher odds compared with nonuse, although not statistically significant. Species-specific analyses showed increased odds of BSIs with Escherichia coli (aOR, 1.33; 95% CI, 1.16-1.53), Staphylococcus aureus (aOR, 1.69; 95% CI, 1.40-2.06), Streptococcus pneumoniae (aOR, 1.46; 95% CI, 1.05-2.04), and Enterococcus faecium (aOR, 1.62; 95% CI, 1.04-2.53). Highest odds were observed in individuals with inflammatory bowel disease (aOR, 2.27; 95% CI, 1.93-2.66), followed by individuals with rheumatoid arthritis. Compared with TNFi monotherapy, concomitant glucocorticoids increased the odds (aOR, 2.63; 95% CI, 2.06-3.36). CONCLUSIONS: TNFi use is associated with increased odds of BSIs and was observed across the most frequent species. Odds varied by TNFi type and underlying disease, with the highest odds among patients with inflammatory bowel disease, emphasizing the need for individualized infection risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor-alphaBacteremiaSepsisTumor Necrosis Factor InhibitorsInflammationHumansCase-Control StudiesFemaleMaleMiddle AgedAgedAdultRisk FactorsInfliximabAdalimumabOdds Ratio

Stichwörter der Autor:innen

BacteremiaBiologic therapyBloodstream infectionCase-control studyDisease epidemiologyInfectiousTumour necrosis factor inhibitors

Substanzen

Tumor Necrosis Factor-alphaInfliximabTumor Necrosis Factor InhibitorsAdalimumab

Autor:innen und Institutionen

  • Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark. Electronic address: Caecilie.leding@regionh.dk.
  • Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital - North Zealand, Hillerød, Denmark.
  • Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents, and Adults, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark; Gastro Unit, Medical Division, Copenhagen University Hospit…
  • Department of Biomedicine, Aarhus University, Aarhus, Denmark; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Section of Rheumatology, Medical Diagnostic Center, Silkeborg Regional Hospit…
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenh…

Zitieren

APA

Leding, C., Meddis, A., Holler, J. G., Burisch, J., Kragstrup, T. W., Skov, L., & Benfield, T. (2026). Tumour necrosis factor-α inhibitors, immune-mediated inflammatory diseases, and bloodstream infections: results from a nationwide case-control study. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2026.02.005

Vancouver

Leding C, Meddis A, Holler JG, Burisch J, Kragstrup TW, Skov L, et al. Tumour necrosis factor-α inhibitors, immune-mediated inflammatory diseases, and bloodstream infections: results from a nationwide case-control study. Clinical Microbiology and Infection. 2026. doi:10.1016/j.cmi.2026.02.005

BibTeX
@article{Leding2026,
  author = {Leding, Cæcilie and Meddis, Alessandra and Holler, Jon Gitz and Burisch, Johan and Kragstrup, Tue Wenzel and Skov, Lone and Benfield, Thomas},
  title = {Tumour necrosis factor-α inhibitors, immune-mediated inflammatory diseases, and bloodstream infections: results from a nationwide case-control study},
  journal = {Clinical Microbiology and Infection},
  year = {2026},
  doi = {10.1016/j.cmi.2026.02.005}
}
Kostenlos starten →